Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00402506 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG
A Phase 3 study of Myocardial Ischemia and Reperfusion Injury, sponsored by Medicure.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,000
- Enrollment target
- 2
- Study locations
NCT00402506: Completed Phase 3 study of Myocardial Ischemia and Reperfusion Injury, sponsored by Medicure.
NCT00402506 is a Phase 3 study of Myocardial Ischemia and Reperfusion Injury that has completed, run by Medicure. The registered enrollment target is 3,000 participants, above the 2,034-participant average among 29 other Myocardial Ischemia trials with a reported enrollment target (47% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00402506, a Phase 3 study of Myocardial Ischemia and Reperfusion Injury, has completed, sponsored by Medicure.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,000 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the effect of MC-1 on the combined incidence of cardiovascular death and nonfatal myocardial infarction (MI) up to and including 30 days following coronary artery bypass graft (CABG) surgery compared with placebo.
Conditions Studied
Interventions
- DRUG (MC-1) Pyridoxal 5'-phosphate
Study Locations (2)
North Carolina
- Duke Clinical Research Institute - Durham
Quebec
- Montreal Heart Institute - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2006-11 |
| Est. Completion | 2007-09 |
| Phase | Phase 3 |
What the finished NCT00402506 record still lists
NCT00402506 is an interventional study that assigns participants to a tested intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, above the 2,034-participant average among 29 other Myocardial Ischemia trials with a reported enrollment target (47% higher).
The record links to 3 conditions, with Myocardial Ischemia appearing as the primary indexed condition, and to 1 intervention - of which (MC-1) Pyridoxal 5'-phosphate is the first listed.
NCT00402506 reports a single indexed study location in North Carolina, Quebec.
Frequently Asked Questions
What is clinical trial NCT00402506 about?
NCT00402506 is a clinical study titled "A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG". The purpose of this study is to determine the effect of MC-1 on the combined incidence of cardiovascular death and nonfatal myocardial infarction (MI) up to and including 30 days following coronary artery bypass graft (CABG) surgery compared with placebo.
What is the current status of trial NCT00402506?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,000 participants. The study started on 2006-11. Estimated completion is 2007-09.
What conditions does trial NCT00402506 study?
This clinical trial studies the following conditions: Myocardial Ischemia, Reperfusion Injury, Coronary Artery Bypass Graft Surgery.
What interventions are being tested in trial NCT00402506?
The interventions under investigation include: (MC-1) Pyridoxal 5'-phosphate (DRUG).
Who is sponsoring clinical trial NCT00402506?
This trial is sponsored by Medicure, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00402506 being conducted?
This trial has 2 study locations across North Carolina, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myocardial Ischemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00402506's enrollment target sits among peer trials
3,000 8th of 29 higher than 22 of 29 other Myocardial Ischemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myocardial Ischemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
COMPLETED · Phase 3
-
Electromechanical Mapping to Evaluate Heart Muscle
COMPLETED · Phase 3
-
Precision of the Magnetocardiographer for Data Aquision and Analysis.
COMPLETED · Phase 3
-
SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes
COMPLETED · Phase 3
-
Safety and Efficacy of MCG for Diagnosing Coronary Heart Disease
COMPLETED · Phase 3
-
Bright Light Exposure in Surgical Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia